Skip to main content

Index Ventures Closes $300M Fund for IT, Life Science Companies

NEW YORK, July 9 – Index Ventures has closed a new $300 million fund to target information technology and life sciences companies in Europe, the firm said Monday.

A spokeswoman said the firm would target life science businesses developing post-genomic platforms, therapeutics, and nanotechnology.

Index, based in Geneva, Switzerland, would most likely devote about 30 percent of the fund to life science companies, the spokeswoman said. Index has invested in six or seven biotechnology companies in the past, including Genmab, a developer of fully-human antibodies based in Copenhagen, Denmark, and Cellzome, a functional proteomics company based in Heidelberg, Germany. 

With the current fund, Index Ventures II, the firm will focus slightly more heavily on life sciences than in the past, according to the company. Index now has a four-person team devoted to identifying early-stage life science companies.

Index invests primarily in European companies, but does consider US and Israeli companies that have early intentions to expand into Europe, or have strategic partnerships with European companies.

Investors in the current fund include UBS Capital, LGT Capital Partners, HarbourVest, and Standard Life Investments.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.